Your browser doesn't support javascript.
loading
Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center.
Kron, F; Kostenko, A; Scheffler, M; Müller, D; Glossmann, J-P; Fischer, R; Michels, S; Nogova, L; Hallek, M; Zander, T; Wolf, J.
Affiliation
  • Kron F; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
  • Kostenko A; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
  • Scheffler M; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
  • Müller D; Institute of Health Economics and Clinical Epidemiology, University of Cologne, Germany.
  • Glossmann JP; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
  • Fischer R; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
  • Michels S; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
  • Nogova L; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany.
  • Hallek M; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
  • Zander T; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
  • Wolf J; Department I of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany; Lung Cancer Group Cologne (LCGC) and Network Genomic Medicine (NGM) Lung Cancer, Germany. Electronic address: juergen.wolf@uk-koeln.de.
Lung Cancer ; 108: 134-139, 2017 06.
Article de En | MEDLINE | ID: mdl-28625625
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Coûts et analyse des coûts / Tumeurs du poumon Type d'étude: Diagnostic_studies / Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Aged / Female / Humans / Male / Middle aged Pays/Région comme sujet: Europa Langue: En Journal: Lung Cancer Sujet du journal: NEOPLASIAS Année: 2017 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: Irlande
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Coûts et analyse des coûts / Tumeurs du poumon Type d'étude: Diagnostic_studies / Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Aged / Female / Humans / Male / Middle aged Pays/Région comme sujet: Europa Langue: En Journal: Lung Cancer Sujet du journal: NEOPLASIAS Année: 2017 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: Irlande